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Efﬁcient communication of a clinical study protocol and case report forms during all stages of a human
clinical study is important for many stakeholders. An electronic and structured study representation for-
mat that can be used throughout the whole study life-span can improve such communication and poten-
tially lower total study costs. The most relevant standard for representing clinical study data, applicable
to unregulated as well as regulated studies, is the Operational Data Model (ODM) in development since
1999 by the Clinical Data Interchange Standards Consortium (CDISC). ODM’s initial objective was
exchange of case report forms data but it is increasingly utilized in other contexts. An ODM extension
called Study Design Model, introduced in 2011, provides additional protocol representation elements.
Using a case study approach, we evaluated ODM’s ability to capture all necessary protocol elements
during a complete clinical study lifecycle in the Intramural Research Program of the National Institutes
of Health. ODM offers the advantage of a single format for institutions that deal with hundreds or thou-
sands of concurrent clinical studies and maintain a data warehouse for these studies. For each study
stage, we present a list of gaps in the ODM standard and identify necessary vendor or institutional exten-
sions that can compensate for such gaps. The current version of ODM (1.3.2) has only partial support for
study protocol and study registration data mainly because it is outside the original development goal.
ODM provides comprehensive support for representation of case report forms (in both the design stage
and with patient level data). Inclusion of requirements of observational, non-regulated or
investigator-initiated studies (outside Food and Drug Administration (FDA) regulation) can further
improve future revisions of the standard.
Published by Elsevier Inc.1. Introduction
There are increasing pressures to lower the cost of conducting
human clinical studies. One way to achieve this is to streamlinethe communication of clinical study protocol information to study
sites and other stakeholders, such as trial registries or institutional
review boards (IRBs). Because completed clinical studies represent
a signiﬁcant past investment and the need to re-analyze the data is
common, many institutions that are consolidating data from clini-
cal studies into larger repositories will beneﬁt from such stream-
lining as well. A meta-analysis [1] reported that between 9% to
49% of randomized control trials report on outcomes that were
not declared in a trial registry. This indicates that post hoc analyses
can be quite frequent. Public pressure for comprehensive sharing
of clinical study data will likewise beneﬁt from improved exchange
of study data and metadata [2].
Table 1
Parts of study documentation and study results with relevant policies and stakeholders.
Study stage Data elements Relevant policies Receiving entity
Study design
documentation
Study protocol Study registration information: US law, WHO list
of required elements, ICMJE
Study registration information: trial registry,
medical journal
Study protocol: ICH Good Clinical Practice
guideline
Study protocol: IRB
Case report forms US law (submission to FDA; 21CFR11), HHS
Interoperability Speciﬁcation, HHS Structured
Data Capture initiative
IRB (some CRFs), study sites, research
coordinators
Study results Basic summary results (public disclosure) US law, EU law (EMA regulations) trial registry, medical journal, reviewers,
authors of meta-analyses
Individual patient level data (disclosure
limited to regulator or research team)
US law (submission to FDA), NIH data sharing
guideline
Regulatory authority (approval of new
products), trial results sharing platforms (eg,
dbGaP)
Abbreviations: ICMJE: International Committee of Medical Journal Editors; ICH: International Conference on Harmonization; WHO: World Health Organization; HHS: US
Department of Health and Human Services; FDA: Food and Drug Administration; EMA: European Medicines Agency.
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above motivations for standardizing protocol information. We
use an example of one NIH protocol to examine the issues of stan-
dardization and explore the suitability of the Clinical Data
Interchange Standards Consortium (CDISC) Operational Data
Model (ODM) standard to facilitate exchange of clinical protocol
data. In contrast to prior studies, we evaluate the use of a single
format that could cover the complete study life-cycle from study
inception to termination and sharing of study results data.
2. Background
2.1. Protocol structure
A clinical study (or protocol) goes through several stages, includ-
ing protocol drafting by a research team, protocol submission and
approval by one or more IRBs, study registration within a clinical
trial registry, study recruitment pre-screening (pre-screen recruit-
ment questions), actual patient recruitment at the study site
(in-person recruitment questions), and collection of study data, per-
haps using electronic Case Report Forms (eCRF) within a Clinical
Trial Data Management System (CTDMS) or an electronic health
record (EHR).
Ideally, protocols should be represented in a format that sup-
ports common protocol data elements, such as study title, locations
or enrollment goal, as well as stage-speciﬁc data and metadata ele-
ments, such as information required for IRB approval, sharing
study details and study eCRFs with all study sites (including clini-
cal research organizations or sponsors), and submission of ﬁnal
data to a statistician, regulator or data sharing platform. A single
format for all these tasks, from study drafting (prior to enrolling
the ﬁrst patient) through study completion and follow-up (after
the last patient’s data have been collected) would be preferable.
We deﬁne a study protocol as a detailed document that is typi-
cally 10–80 pages long and includes the study schedule, detailed
description of all study events as well as other elements deﬁned
by the Good Clinical Practice guideline (E6) [3] from the
International Conference on Harmonization. This guideline, which
was created with input from US as well as EU authorities, stan-
dardizes numerous protocol sections, such as, withdrawal criteria,
blinding or adverse event reporting. Within the protocol, we also
distinguish a short set of study metadata elements that we refer
to as study registration information (such as title, principal investi-
gator, research sites, study design, or enrollment goal). These ele-
ments are typically required by trial registries or internal study
administration systems.
Table 1 provides an overview of different study documentation
components, as well as relevant policies for each component. Weconsider design of case report forms to be an important attach-
ment to the study protocol and an integral part of good study doc-
umentation. Study protocols are also needed when study results
are obtained and communicated, and hence we also include in
Table 1 study results data elements. These include summary data
that are required by some trial registries (and by US law) and indi-
vidual patient level data, that are needed for submission to a reg-
ulator or to some data sharing platforms (eg, TrialShare from
National Institutes of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network) [4]. The resulting representation will
need to be computable, for example, an Extensible Markup
Language (XML) ﬁle that can be consumed both by information
systems and by humans (after transformation into formats such
as Hypertext Markup Language (HTML) or Portable Document
Format (PDF).
Existing standards cover to some extent the representation of
study registration information and CRFs; however, there are no
standards capable of transporting (in a structured sense) the full
protocol document. The dominant standard development organi-
zation (SDO) for creating clinical research informatics standard is
the Clinical Data Interchange Standards Consortium (CDISC), which
was established in 1999. CDISC standards development efforts are
organized into different workgroups, with the Protocol
Representation Group (formed in 2002) working to create such a
standardized format. CDISC intends to use this or a similar format
to standardize submission of protocol data to clinical trial reg-
istries. For example, currently it is not possible to use a single for-
mat to submit clinical study data to USA’s clinical trial registry
(ClinicalTrials.gov) and EU’s registry run by European Medicines
Agency (EMA).
2.2. Prior work in protocol representation
2.2.1. ODM-based work
Protocol representation formats have been the subject of sev-
eral prior studies. The most relevant standard is the CDISC
Operational Data Model. Prior studies using ODM focused mostly
on case report forms, rather than strictly on protocol representa-
tion. Bickel et al. developed an i2b2-based tool that can import
the CDISC ODM formatted data into an i2b2-based data warehouse
[5]. Dugas at al. developed a Web-based platform [6] and an R
package [7] supporting exchange of empty eCRFs in ODM format.
Karam et al. from World Health Organization developed an ODM
extension focused on clinical trial registration [8]. ODM was one
of the ﬁrst standards developed by CDISC and it was meant from
the start to be a foundation standard with building blocks for cap-
turing a range of clinical study data. ODM was initially created in
1999 with updates to version 1.3 in 2005 and a small update to
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requirements for transporting case report data between research
collaborators (e.g. sponsors, clinical research organization, elec-
tronic data capture vendors and others) including adherence to
US regulatory requirements (21CFR11) for data provenance and
electronic signatures. ODM has pre-deﬁned XML elements that
can represent protocol-level metadata (Study element), single case
report form data (FormDef element), form sections (ItemGroupDef
element), individual CRF questions (ItemDef element) and allow-
able values for questions (CodeListDef element). The standard is
essentially an XML schema with an accompanying schema usage
speciﬁcation document. In addition to its function as a
stand-alone standard, it is also a foundation for several other stan-
dards: Deﬁne-XML, Dataset-XML [9] and Study Design Model
(SDM). All of these standards are based on the foundational syntax
deﬁned by ODM and are, in an XML-schema sense, ODM XML
schema extensions. Comprehensive protocol representation was
outside the initial focus of ODM and only later extensions, such
as SDM, focused on this issue.
2.2.2. Other relevant prior work and related standards
To separate the various forms of eCRFs and recruitment stages,
Weng at al. deﬁned the concept of pre-screening [10] and analyzed
whether EHR records can be used to pre-screen potential research
subjects. Richesson at al. looked overall at clinical research infor-
matics standards [11] and identiﬁed gaps that exist [12]. In
Europe, the Electronic Health Records for Clinical Research
(EHR4CR) project is attempting to integrate collection of clinical
study data within EHRs and is using ODM as the main standard.
In the US, the Ofﬁce of the National Coordinator for Health
Information Technology is working to improve standards adoption
by US EHR manufacturers through the Structured Data Capture
Group of its Standards & Interoperability Initiative. The
ClinicalTrials.gov team developed an XML schema that is used to
register trials [13]. Finally, the NIH framework for deﬁning and
coordinating clinical research Common Data Elements (CDE) aims
to enable data collection harmonization across studies [14].
Besides the CDISC ODM, there are other relevant CDISC stan-
dards and models, such as the Study Data Tabulation Model
(SDTM) and Deﬁne-XML that are regulatory submission standards.
However, the majority of prior protocol data exchange efforts use
the more generic CDISC ODM standard.
A high level CDISC conceptual model called BRIDG is another
candidate protocol representation framework. BRIDG was ﬁrst
introduced in 2006, seven years after the creation of ODM. CDISC
strives to align all current and future standards to this common
domain model that speciﬁes basic elements such as investigator,
subject, study or intervention. BRIDG is expected to be a ﬁnal
International Standard Organization (ISO) standard by April 2015
(it passed draft international standard ballot in January 2015).
Most recently, standard integration efforts are most apparent
within the CDISC Shared Health and Clinical Research Electronic
Library (SHARE) [15]. SHARE was initially made available to
CDISC Platinum members and it will be made available to others
pending an appropriate business model for sustainability.
BRIDG was also embraced by Health Level 7 and International
Organization for Standardization (ISO), FDA and National Cancer
Institute. There are no published reports or roadmaps that com-
ment on how well the latest version of ODM is harmonized with
the central BRIDG model. While BRIDG is potentially a much more
comprehensive model, our choice to use ODM was driven by the
fact that BRIDG, as a Uniﬁed Modeling Language (UML) model,
does not offer a well-deﬁned data storage format. In other words,
it is not possible to use several Uniﬁed Modeling Language tools
to model a single clinical trial using BRIDG, and be certain to pro-
duce identical ﬁles (e.g., NCT001234.BRIDG).2.3. Institutional background
In this article, we use a case study approach in which we ana-
lyze the complete protocol lifecycle of a single protocol in the
National Institutes of Health (NIH) Intermural Research Program
(IRP). The intramural research program has currently over 2300
active protocols (as of August 2014). On average, 231 new proto-
cols are initiated every year. Since 1953, the Intramural Research
Program has registered a total of 8017 completed studies and
maintains a repository [16] of data collected in those studies.
Approximately half of the studies are observational natural history
studies (based on an analysis of 1155 intramural studies initiated
during the last 5 years). To better illustrate the protocol represen-
tation and communication challenges, we provide below a brief
description of the protocol lifecycle in the Intramural Research
Program.
There are several large intramural IT systems, and each needs to
represent slightly different clinical study metadata or various types
of case report forms (see also Fig. 1 and Table 2). ProtoType is a
Web-based protocol authoring tool used by some intramural
investigators during protocol drafting. Finalized protocols are then
passed to the IRBs which use electronic eIRB systems to track each
submitted and approved study. At NIH, there are 10 IRBs and they
use one of the two kinds of eIRB systems (referred to as PTMS and
iRIS; see Appendix A for a full overview). In our analysis, we focus
on the home-grown PTMS systems because of greater control over
its features. If a study is approved by the IRB, the NIH Ofﬁce of
Protocol Services imports study data into a repository of active
study protocols (called ProTrak). Among other tasks, the ProTrak
system and the ProTrak team registers the study in the
ClinicalTrials.gov registry (as required by US law for certain types
of interventional studies).
Approved and registered studies may initiate patient recruit-
ment, which is facilitated (for studies that choose to do so) by
the NIH Patient Recruitment and Public Liaison (PRPL) Ofﬁce. The
Recruitment Team maintains a database of research volunteers
and tracks every study phone screening session within the
Recruitment Volunteer System (RVS) [17]. RVS enrollment criteria
are speciﬁed in the IRB protocol as phone screening CRFs. If a patient
meets pre-screening phone criteria, his contact information is
passed on to the study research coordinator who typically arranges
in-person screening visit at the research clinic. Screening visit data
are driven by screening CRFs and protocol event schedules (such as
screening laboratory tests procedures). Protocol-speciﬁc eCRF data
are recorded within a CTDMS (eg, Pelvic Pain Screening
Questionnaire). Within the Intramural Research Program, a total
of 6 different CTDMSs are used. See Appendix A for a full list. The
most widely used is Clinical Trial Database (CTDB). Other relevant
study data (eg, blood sample laboratory results or EKG) are
recorded within an EHR system. The main intramural EHR system
is currently Allscripts Sunrise Clinical Manager. Data from the EHR
and some CTDMSs are integrated into a data repository called the
Biomedical Translational Research Information System (BTRIS)
[16]. For researchers conducting secondary analyses executed
within BTRIS, protocol metadata of terminated protocols are
needed for proper data interpretation. For example, data from
‘Natural History’ studies are usually longitudinal and come from
multiple visits while data from a ‘Phase 1 Clinical Trial’ study type
may be limited to a single visit.
Table 2 shows an overview of various systems that need to
represent protocol data and what representation standards
they currently support. The last column indicates whether the
CDISC ODM standard contains all necessary ﬁelds to be able to
replace the current standard and whether ODM is currently used.
A graphical overview of data ﬂow is provided in Fig. 1. We set
out to investigate the best standard and mechanism that would
Fig. 1. Research systems overview.
Table 2
Relevant NIH and external systems for protocol representation.
System Purpose (responsible department or user) Import/export
capabilitya
Standards
used
ODM support (ODM
used)
ProtoType Authoring tool (PI team) No/yes .doc/.XML Partial (no)
iRIS eIRB system 1 (IRB) No/no None Partial (no)
PTMS eIRB system 2 (IRB) No/no None Partial (no)
ProTrak Administration (Ofﬁce of Protocol Services) No/no None Partial (no)
ClinicalTrials.gov Trial registry (external entity) Yes/yes .XML Partial (no)
RVS Patient recruitment and reimbursement (Patient Recruitment and Public
Liaison)
No/no None Comprehensive (no)
CTDB Electronic data capture (research team/patient self-reporting) No/yes None Comprehensive (no)
EHR (sunrise clinical manager) Patient care (IT department) No/yes HL7 C-CDA Comprehensive (no)
BTRIS Data monitoring, analysis (Laboratory for Informatics Development) Yes/yes .csv, .XML,
other
Comprehensive
(partially)
Statistical system (R, SAS or
other)
Statistical analysis (research statistician) Yes/yes .csv, .XML,
other
Comprehensive
(partially)
FDA Drug approval (external entity) Yes/– SDTM, ODM Comprehensive (yes)
dbGaP Data sharing (external entity) Yes/yes .csv, .XML,
other
Comprehensive (no)
a PDF format was excluded as a valid import/export format.
V. Huser et al. / Journal of Biomedical Informatics 57 (2015) 88–99 91support moving protocol data and metadata across these
stages/systems.3. Methods
We demonstrate the challenges of protocol representation
using a case study approach. We selected a single protocol (‘‘The
Safety and Effectiveness of Surgery with or without Raloxifene
for the Treatment of Pelvic Pain Caused by Endometriosis’’) and
modeled its data representation in various stages of its lifecycle.
Throughout this article, we use the word ‘‘study’’ or ‘‘trial’’ to refer
to the raloxifene trial and the word ‘‘analysis’’ to refer to ourrepresentation format analysis. For each study stage, we quanti-
ﬁed, where possible, the number of study elements that could be
represented directly in ODM. For some study stages, where we
found that ODM provides limited support and coverage, we inves-
tigated and described which other CDISC standards could be used
instead.
The majority of the protocols of completed intramural research
studies are available as PDF documents which are image scans of
the paper protocols. We identiﬁed the raloxifene ﬁle and converted
it into a textual format. We used the WmHelp XMLPad editor (ver-
sion 3.0.2.1; available as freeware from xmlpad-mobile.com) to
create the study ODM ﬁles. We pre-loaded the ODM XML schema
(version 1.3.2) to enable XML schema validation while editing
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DesignModel (SDM) offers improved support for some studymeta-
data, we have also added the SDM XML in addition to the ODM
schema. This is a preferred approach recommended by CDISC, since
SDM was released as an extension to the ODM schema. In addition
to the XML editor, we also used a Web-based wizard tool [18] for
creating CDISC study outline ﬁles. To facilitate accurate character-
ization of the study lifecycle, we delineate several study stages
below and provide additional stage-speciﬁc methodological, insti-
tutional or informatics context.
3.1. Study drafting
The goal of the study drafting stage is to generate study regis-
tration information and the full protocol that describes the steps
and procedures of the protocol. These data are needed to either
support a study funding decision process or to communicate the
study to the larger research team or external study sites.
3.1.1. Study initial registration data
The Intramural Research Program standardized data relating to
the registration of the study itself (as opposed to registration of
research subjects) by instituting a common form (Initial Review
Application; formerly referred to as form 1195). The full form is
available at http://dx.doi.org/10.6084/m9.ﬁgshare.1096216. It con-
tains, for example, ﬁelds for protocol title, subject accrual charac-
teristics, protocol type and phase, principal and associate
investigators, and related FDA identiﬁers, such as Investigational
New Drug [IND] or Investigational Device Exemption [IDE]).
Because study registration data are required by many systems,
most investigators provide them in structured form either in the
ProtoType system or in an eIRB system. Neither ProtoType nor
PTMS support export of these data in a structured form.
ProtoType allows export of the data in Microsoft Word format
and PTMS supports generation of a PDF ﬁle that recreates the
1195 form. Fig. 2 shows structured data entry of form 1195 subject
accrual characteristics data within ProtoType.
3.1.2. Study protocol
The study drafting stage also involves creation of the detailed
protocol. The majority of protocols in the NIH IntramuralFig. 2. Entering initial review applicaResearch Program are authored in word processing software (e.g.,
Microsoft Word) and communicated in Ofﬁce Open XML format
(.docx) or PDF format.
PTMS, in the current version, does not support authoring the
full protocol. The ProtoType system, on the other hand, enables
principal investigators to author protocols using a Web-based sys-
tem. In contrast to using word processing software on a local PC,
ProtoType provides team features such as protocol commenting
and approval by collaborating scientists. Similar to word process-
ing software, it offers the ability to add images and references to
any part of the protocol. By requiring entry in some protocol sec-
tions, it encourages data completeness.
3.2. Study registration
Because registration of most interventional clinical studies is
required by US law, we consider submission to a trial registry in
a separate registration stage. In the Intramural Research Program,
the ProTrak system and team facilitate submission of data to the
ClinicalTrials.gov registry. Data entered into ProTrak and submit-
ted to the registry can be re-used to extend the protocol metadata
created in the study drafting stage.
3.3. Study initiation and execution
The study initiation stage starts upon IRB approval. In order to
collect patient level data, one or more CRFs must be deﬁned. In a
multi-site trail, each site may be using a different electronic data
capture system and the ability to import and export CRFs is an
important function of a protocol representation format and can
save time spent on duplicate entries of the same CRFs into multiple
system. It is important to note that communication of empty CRFs
is free of any patient privacy considerations because only empty
forms are being transmitted. In our analysis of this study stage
we focus on empty CRFs representations in this stage and consider
CRFs with patient level data in the next stage.
3.4. Study termination
The study termination phase begins when last patient data are
collected. During the study termination phase, a data capturetion form data within ProtoType.
Table 3
Overview and usage of case report forms in the raloxifene trial.
Case report form name # of collected forms
Quality of life questionnaire 520
Pelvic pain questionnaire 519
Sexual function questionnaire 517
Symptoms questionnaire 513
Pelvic pain diagram 403
Headache follow up 289
Bone density questionnaire (interval) 234
Dexa 224
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protocol representation (see Table 1). Export of collected data for
analysis is the most important step in the termination phase. A
data export, however, may also occur during the study execution
phase to support, for example, interim study monitoring by the
Data Safety Monitoring Board (DSMB) (e.g., premature termination
of the study due to lack of efﬁcacy or other reasons). A standard-
ized export of study data is helpful to statisticians, who deal with
multiple studies, or to data repositories responsible for long-term
storage of clinical study data.Endometrial biopsy 203
Headache 174
Surgical ﬁndings 147
Consultation 142
Complications 140
12–21 month assessment 140
1st pre-op information 135
Or pathology report 135
Baseline general assessment 130
Pelvic pain screening questionnaire modiﬁed 115
Adhesions form 104
Patient status 93
3 month assessment 83
6 month assessment 72
9 month assessment 53
Unscheduled ultrasound 48
24 month assessment/2nd pre-op form 43
Total 51764. Results
4.1. Analyzed protocol
The selected protocol ‘‘The Safety and Effectiveness of Surgery
With or Without Raloxifene for the Treatment of Pelvic Pain
Caused by Endometriosis’’ is a description of the trial registered
at ClinicalTrial.gov under identiﬁcation number NCT00001848
(http://clinicaltrials.gov/show/NCT00001848). The trial examined
whether 6 months of raloxifene was effective in the treatment of
chronic pelvic pain in women with endometriosis. Women with
chronic pelvic pain underwent laparoscopy and were randomly
allocated to raloxifene or placebo. A second laparoscopy was per-
formed at 2 years, or earlier, if pain returned. Detailed study results
for raloxifene are available in the primary trial result publication
[19] with additional publications describing secondary analyses
of migraine prevalence [20] and the relationship of pain location
to biopsy-proven lesions [21]. The study data collection was com-
pleted in 2004. We obtained the permission of the study principal
investigator to use trial’s empty case report forms and parts of the
protocol for our analysis.
4.1.1. CRF data
The raloxifene trial had 25 forms deﬁned with a total number of
686 questions. The most used forms were ‘Quality of life question-
naire’, ‘Pelvic Pain Questionnaire’ and ‘Sexual Function
Questionnaire’. See Table 3 for complete overview. The trial had
10 study intervals deﬁned (e.g., Screening, Baseline, 3 Month, 6
Month, 9 Month, 24 Month) with many forms assigned for
repeated collection at multiple intervals.
4.2. Analysis by study stage
4.2.1. Study drafting
4.2.1.1. Study initial registration data. The Supplemental File S1 con-
tains all protocol metadata available within ODM that are typically
speciﬁed during early study drafting. Most of those are elements
from the NIH form 1195. The elements directly supported by
ODM were: title, study ID, and study description (also referred to
as study précis). Using the SDM extension, we were also able to
capture study inclusion and exclusion criteria (as a free text block,
without separating individual criteria). Ideally, text-based criteria
would be augmented with annotations that could facilitate com-
puterized determination of eligibility [22,23]. Such a feature would
currently be only achievable via an additional ODM extension or a
revision of the existing SDM extension.
ODM lacks designated XML elements to represent brief title, sci-
entiﬁc keywords, study type (observational, interventional), inter-
ventional trial phase (0,1,1-2,2,3,4), inclusion of healthy
volunteers, use of ionizing radiation (yes/no ﬂag), or capturing of
associated identiﬁers for Investigational New Drug (IND) applica-
tion or Investigational Device Exemption (IDE) that are associated
with a study. The study drafting data also include the names of the
principal investigator, the contact for scientiﬁc queries, and thecollaborators (such as lead associate investigator, associate investi-
gators and medical advisory investigator). While these additional
contacts can be represented in ODM using the ‘‘User’’ element with
an optional UserType attribute, ODM does not mandate the use of
any commonly used user types (e.g. principal investigator). The
ODM User element is predominantly meant for management of
data access for clinical study coordinators at various study sites
during the study execution stage. Possible changes to the ODM
model suggested in the charter of the newly formed CDISC
Clinical Trials Registration group (CTR) may improve ODM support
for this study phase [24]. Moreover, such changes should not only
consider minimum regulatory data elements but also elements
that would facilitate protocol-level data exchange between
research systems, such as eIRB systems.
4.2.1.2. Study Protocol. We converted the raloxifene study protocol
PDF into a structured HTML5 (Hypertext Markup Language) docu-
ment using optical character recognition in combination with man-
ual editing and review. Since ODM provides almost no support for
representing the full protocol (except for brief study description
ﬁeld), the most optimal way to model these data is via an institu-
tional ODM extension. The Raloxifene protocol sections are shown
in Fig. 3.
However, limited capture of protocol data is possible using
other CDISC models and tools. The CDISC Protocol Representation
(PR) Group [25] developed between 2002 and 2010 a set of more
than 300 standardized protocol concepts (such as study objective,
phase, design, study population age criteria) that were modeled in
the Uniﬁed Modeling Language (UML). CDISC formally released
this set in 2010 as the Protocol Representation Model v1.0
(PRM). The CDISC PR group included representatives from aca-
demic medical centers and pharmaceutical companies, WHO,
EMEA and NIH. The resulting PRM model was harmonized with
the CDISC common BRIDG model. To illustrate the content of
PRM, Appendix A includes an overview of all PRM sections and a
subset of elements within each section with links to the corre-
sponding part of the IHC Good Clinical Practice E6 guideline.
Due to limited adoption of UML-based tools by principal inves-
tigators and study managers [26], in 2011 CDISC released a subset
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Study Design and Methods
Inclusion and Exclusion Criteria
Study Procedures (by stage)
• Screening
• Medical Treatment
• Monitoring
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Fig. 3. Sections deﬁned in the raloxifene detailed scientiﬁc protocol.
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protocol outline) and provided a Microsoft Word template [28] that
enables protocol writers to enter semi-structured content using a
standard and familiar word processor software. The purpose of
the protocol outline, also referred to as ‘‘Study Synopsis’’ or
‘‘Study Concept Sheet’’, is to provide an outline of the key concepts
which deﬁne the study design prior to commencing authorship of
the full protocol and development of individual study CRFs.
Supplemental ﬁle S2 demonstrates the protocol outline data for
the raloxifene trial that uses the provided template. In addition to
the template, CDISC provides a link to a Web-based protocol
authoring tool [18] that can generate a protocol outline ﬁle in
PDF and CSV format. A protocol outline subset includes elements
that directly populate the study metadata required for FDA sub-
mission (elements of the Trial Summary domain in the Study
Data Tabulation Model). Supplemental ﬁles 3a, 3b and 3c show
the PDF ﬁle and two comma separated value ﬁles (representing
the CDISC Study Data Tabulation Model format) for the raloxifene
trial that were created with the Web-based tool.4.2.2. Study registration
ODM provides very limited support for representing study reg-
istration data. Only 7 of the 20 elements deﬁned in the WHO min-
imum trial metadata [8,29,30] can be directly represented in ODM
These are: Scientiﬁc Title, Countries of Recruitment (via the ODM
Location element), Key Inclusion and Exclusion Criteria, and via
the user and user type elements: Source of Monetary or Material
Support, Primary Sponsor, Secondary Sponsor, Contact for Public
Queries and Contact for Scientiﬁc Queries). Appendix A shows a
complete list of all 20 elements together with their mapping to
ClinicalTrials.gov ﬁelds. In some cases, the ClinicalTrials.gov reg-
istry uses multiple ﬁelds to capture a single WHO element. The
newly formed CDISC Clinical Trials Registration group (CTR) is
working toward an ODM extension that addresses the remaining
13 elements (e.g., target sample size) marked in Appendix A as cur-
rently not covered by ODM.
An initial attempt to model study registration data was under-
taken in 2011 as a joint project of CDISC and HL7. The resulting
UML model [31] is the basis of a new project and working group
(Clinical Trials Registry and Results) that is developing a standard
format to reconcile all metadata required by ClinicalTrials.gov
and EudraCT. The targeted format, scheduled to be published in
2014, will be a BRIDG-compatible, ODM-based XML schema that
can be used to electronically exchange registry information
between a study sponsor and a registry organization. Until this for-
mat is available, an alternative approach to such an exchange is the
inclusion of all ClinicalTrial.gov elements using the extensionmechanism of ODM. Supplemental ﬁle S4 shows an example of
implementing this extension-based approach.
Because ClinicalTrials.gov registry collects relatively detailed
study metadata (either at initial study registration or later deposi-
tion of basic summary results), it may be beneﬁcial to import data
entered into ClinicalTrials.gov back into local research systems. We
have created an eXtensible Stylesheet Language transformation
(XSLT) that takes study NCT identiﬁer as input and produces an
ODM ﬁle with mappable ClinicalTrials.gov data. The XSLT ﬁle is
available at http://dx.doi.org/10.6084/m9.ﬁgshare.1096216.
4.2.3. Study initiation and execution
In contrast to the previous two stages, ODM support for the rep-
resentation of CRFs and their patient level data is very comprehen-
sive since those were key design requirements during its creation.
ODM has a thorough set of XML elements to model CRFs. A single
ODM ﬁle can represent one or multiple empty CRFs. In ODM, forms
are divided into sections (ItemGroup elements), which consist of
individual questions (Item elements). A form question may refer-
ence a pre-deﬁned value set (CodeList element). For example a
value set consisting of choices ‘All of the time’(1), ‘Most of the time’
(2), ‘Some of the time’ (3), ‘A little of the time’ (4), and ‘None of the
time’ (5) can be linked to several questions that use the same value
set. A CodeList may use integers (shown above), characters or
strings as identiﬁers for individual code list choices. With such a
value set deﬁnition in place, several questions, such as ‘Did you feel
full of life?’ or ‘Have you been a very nervous person?’ can both ref-
erence such pre-deﬁned value set. If an ODM ﬁle formally deﬁnes
clinical study intervals (StudyEvent element; for example, screen-
ing or 3 month follow up visit), a form deﬁnition may be linked
to zero, one or multiple study intervals. While value set standard-
ization within a study is beneﬁcial, of greater importance is stan-
dardization across studies, which is potentially achievable with
efforts such as National Library of Medicine’s Value Set Authority
Center [32] or Common Terminology Services (CTS 2) [33]. ODM
includes an ExternalCodeList element with an optional URL
attribute that allows linking to external resources. If such a link
is used, however, the standard currently does not specify require-
ments for the format or functionality of the URL link. A binding
guidance (issued by FDA) for regulatory submissions speciﬁes
NIH/National Cancer Institute Enterprise Vocabulary Services as a
terminology resource. With respect to ODM and case report form,
another CDISC initiative called Clinical Data Acquisition Standards
Harmonization (CDASH) [34] aims to provide standardized forms
and form elements, and it is released as an ODM XML ﬁle. It was
ﬁrst released in 2008 and a new version is expected in 2015.
ODM also includes support for branching logic (eg, dynamic
forms that display certain questions based on prior form entries or
prior patient data); however, ODM does not prescribe use of any
speciﬁc expression language, such as XPath or JavaScript. This ﬂexi-
ble, but incomplete approach limits the form portability across var-
ious electronic data capture systems. Supplemental ﬁle S5 shows an
example ODM ﬁle that represents a single form from the raloxifene
trial. Itwas producedby a newly implemented export featurewithin
the intramural electronic data capture system (CTDB).
Even though ODM can represent many CRF features relatively
well, some vendors of electronic data capture systems (eg,
OpenClinica, Formedix, Medidata Solutions or Oracle) and institu-
tions (NIH Intramural Research Program) developed extensions
to handle advanced form features. Examples of features covered
by extensions are: (1) form fonts or colors (eg, color coding or rich
text formatting of certain items in a value set or word emphasis in
a question); (2) presence of images on forms (eg, recording exact
location of pain using a diagram); (3) addition of explanatory notes
linked to particular form questions; or (4) complex rules for check-
ing user-entered values. The current version of ODM focuses
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study data to a regulator. This keeps the standard relatively simple
but requires using extensions which limit portability across sys-
tems. Future revisions of the standard may include additional
requirements for non-regulated studies or requirements for simple
export of empty, but rich formatted forms.
Our provided example focuses on a single form; however, ODM
also supports representation of multiple forms and proper linkage
of individual forms to relevant study events. Table 4 lists several
ODM use scenarios that are possible. The six rows of the table show
a range of possible ODM data exchange scenarios that range from
ranging from a mere protocol description (without any CRFs; rows
1–2) to various forms of CRF exchange (rows 3–5) or a complete
study archival scenario (row 6). The columns of the table indicate
utilization of different high-level groups of ODM elements utilized
in these scenarios.4.2.4. Study termination
Similarly to the study initiation stage, ODM provides good sup-
port for export of patient level data collected via CRFs. Study data
in ODM can be in a snapshot form, which is a copy of the data at a
given time, or in a more detailed, transactional form that includes
full audit trails (prior values for each data point and how it chan-
ged over time). Audit trails can, for example, fully accommodate
double entry CRFs that offer greater data accuracy.
ODM with patient level data can be used to export study data
for ﬁnal analysis (Fig. 1), and for sharing with other researchers
and regulators. Prior to 2014, ODM-based data had to be yet fur-
ther converted into SAS-based XPORT format (.xpt) as speciﬁed
by the CDISC STDM standard. However, since May 2014, the FDA
is exploring possible acceptance of ODM-based submissions (using
CDISC DataSet-XML standard which is essentially a subset of ODM)
in a pilot project. The ODM format can also be used to transmit
study data to interested researchers, as mandated by pioneering
journals (such as the British Medical Journal, Annals of Internal
Medicine or PLoS Medicine [35]) or other initiatives, such as the
Yoda Project [36]. ODM can also be used for sharing de-identiﬁed
patient-level level data, based on the January 2014 statement by
EMA to make data available to independent researchers that wish
to reanalyze the data or conduct new analyses after the marketing
authorization process has completed. Similar development toward
data sharing may be expected from FDA based on June 2013
request for comments (Availability of Masked and De-identiﬁed
Non-Summary Safety and Efﬁcacy Data [37]. Supplemental ﬁle S5Table 4
Listing of multiple possible ODM data exchange scenarios that utilize different high-
level components within ODM.
ODM data
communication
scenario
High-level components of an ODM XML ﬁlea
Basic
protocol
data
Detailed protocol data
with arms and events
Empty
CRF
CRF with
patient level
data
Initial trial
registration
X
Detailed protocol
speciﬁcation
X X
Single form (no
study context)
X
Single form (within
a study context)
X [X]a X
Single form with
data (no study
context)
X X
Archived complete
study results
X X X X
a X indicates use of the ODM elements in a given category. Square brackets
indicate that the scenario may or may not use a given category.provides an example of patient level data collected within the
Surgical Findings CRF (2 made-up patients).5. Discussion
5.1. ODM standard perspective
The ODM standard is the best baseline standard for represent-
ing clinical research study protocol. It natively supports local
extensions for data elements not covered by the canonical stan-
dard. For data repositories, dealing with a single format for study
protocols and study results decreases the development time
required to import studies into the repository or to exchange data
between systems. ODM constructs for value sets, form sections and
study events may also provide guidance for developers of elec-
tronic data capture system and contribute to better data structure
compatibility across studies.
The current ODM version 1.3.2 has limited support for captur-
ing full protocol and study registration data but supports case
report form representation well (in the design phase and with
patient-level data). These limitations exist mainly because this
was not the original use case for creating the standard. Recent ini-
tiatives within CDISC, however, try to increase the coverage either
via additional ODM extensions or a new version of ODM. To further
increase the adoption of ODM as a data exchange standard among
research systems, focus on satisfying minimum data exchange
needs in addition to data elements required for a regulatory sub-
mission is critical.
Inclusion of requirements of observational, non-regulated or
investigator-initiated studies (outside FDA context) can further
improve future versions of the standards. For example, addition of
more user roles, study type and phase, capturing full protocol sec-
tions, support for rich-text formatting and more restricted syntax
for CRF data validation. One of the authors (VH) participates within
CDISC CTR&R, PR and XML groups to facilitate such a change.
For long-term data storage, an important feature of ODM is the
annotation of CRF questions with coded concepts from any termi-
nology (eg, SNOMED or LOINC) or data element deﬁnition scheme
(eg, Common Data Elements) [14]. Such annotation can facilitate
discovery of relevant data by users of large data repositories. A
minor limitation of this annotation feature is that annotations
are linked to the whole questions and cannot reference particular
parts of the questions. For example, a form question ‘‘Are you preg-
nant or breast feeding?’’ would be annotated as a whole with two
coded concepts as opposed to a more elaborate structure, such as
‘‘Are you [pregnant (SNOMED:77386006)] or [breast feeding
(SNOMED:69840006)]?’’.
Another important feature, somewhat outside the scope of pro-
tocol representation, is actual use of ODM by healthcare institu-
tions and EHR vendors. The ability to present a research form at
the right time inside an EHR system is a feature that has been
implemented using ODM [38]. El Fadly at al. described a RE-USE
project that uses ODM metadata message to create an empty
research form in the EHR, and the use of an ODM mediator to
exchange the form data [39]. ODM is also the standard of choice
used in the Retrieve Form for Data-capture (RFD) proﬁle main-
tained by the Integrating Healthcare Enterprise (IHE). A related
IHE standard, called Retrieve Process for Execution, aims to facili-
tate automation of protocol related processes speciﬁed by the pro-
tocol study design. CDISC published that GE, Cerner, Allscripts,
Epic, Greenway, Tiani Spirit and eMDs vendors implemented the
Retrieve Form for Data capture capabilities; however, there are
few or none published reports on its use in recent research trials.
The US meaningful use regulations that advocated for greater use
of healthcare IT did not include any mandate of EHR systems to
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5.2. Institutional perspective
From an institutional perspective, the beneﬁts of using ODM
depend on the overall volume of studies, proportion of studies
eventually submitted to FDA and enterprise electronic research
systems used at a given site. During study drafting and registration,
the overall volume of study data is very limited and repeated
entering of the data into various systems is feasible. The size of
the protocol data increases greatly in the study initiation phase
(empty CRFs speciﬁcations) and the motivation for standardization
in this phase is greater. Standardization beneﬁts are most apparent
for multi-site studies using multiple electronic data capture sys-
tems (non-centralized) and for studies later submitting data to
the FDA or data sharing platforms. Proper study representation
has the greatest value when data are re-analyzed by investigators
that have no or limited access to the principal investigator of the
original study (eg, the original PI has left the institution). Use of
ODM from the study inception greatly simpliﬁes export of study
data for submission to the FDA. This approach is widely advocated
for and referred to as CDISC-end-to-end approach [40].
5.3. Study limitations and future work
Our analysis of protocol representation using ODM is limited by
the fact that we used only a single interventional study and the
context was only a single research institution. In selecting the
raloxifene trial as a case study, we ﬁrst identiﬁed all terminated
interventional trials that contributed CRF data into our institu-
tional data repository and ordered them in descending order by
total count of research forms deﬁned. We picked the most complex
study for which we were able to secure the permission of the study
principal investigator to use his/her study for an informatics anal-
ysis. By using a set of several studies with different study designs
instead of a single study, we would most likely arrive at a more
comprehensive ODM evaluation. In terms of future work, we have
explored and hope to continue to explore archiving of intramural
research studies using ODM (including, for example, screening pro-
tocols that are not subject to mandatory registry submission) and
the potential use of ODM in submitting data to trial data sharingAppendix A
A.1. eIRB systems and overview of IRBs within the Intramural Research Pr
IRB # of Assigned New
Studies (2009–2014)*
National Heart, Lung, and Blood
Institute (NHLBI)
121
National Human Genome Research
Institute (NHGRI)
57
National Institute of Allergy and
Infectious Diseases (NIAID)
153
National Cancer Institute (NCI) 330
National Cancer Institute – IRB for
Special Studies (NCI-SS)
58
Eunice Kennedy Shriver National
Institute of Child Health and
Human Development (NICHD)
52
National Institute of Environmental
Health Sciences (NIEHS)
26platforms. The ﬁrst author (VH) also participates within the
CDISC XML team in several initiatives relevant to protocol
representation.6. Conclusions
ODM supports a growing number of protocol metadata ele-
ments and it offers advantages of a single format for institutions
that have to deal with hundreds or thousands of concurrent clinical
studies and maintain a repository with data from all completed tri-
als. For each study stage we presented a list of gaps in the standard
and necessary vendor or institutional extensions that can compen-
sate for such gaps together with an institution-centric and
life-time view of the trial. Protocol representation was outside of
ODM’s initial focus of exchange of case report form data; however,
existing and emerging extensions and use cases will most likely
increase support for protocol-level metadata within ODM.Conﬂict of interest
The authors have no conﬂict of interest to report.
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IRB # of Assigned New
Studies (2009–2014)*
eIRB system Additional institutes
Central Nervous System Combined
IRB
225 PTMS National Institute of Neurological Disorders
and Stroke (NINDS), National Eye Institute
(NEI),National Institute of Mental Health
(NIMH), National Institute of Dental and
Craniofacial Research (NIDCR), National
Institute of Deafness and Other
Communication Disorders (NIDCD)
Addictions IRB 52 PTMS National Institute on Drug Addiction (NIDA),
National Institute on Alcohol and Alcoholism
Addiction (NIAAA)
National Institute of Diabetes and
Digestive and Kidney Diseases
(NIDDK)
66 PTMS National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS)
* Counts are provided for studies in the last 5 years (studies with start date between January 2009 to August 2014).
A.2. Clinical Trial Data Management Systems used within the Intramural Research Program
Only systems contributing data to the BTRIS central intramural data repository are shown.
System Institute System developer Primary system use case(s)
Clinical Trials Database (CTDB) NICHD, NIAAA,
NIDDK, Clinical Center
NICHD Encounter Forms
Labmatrix NCI Commercial Biospecimens
Cancer Central Clinical Database
(C3D)
NCI NCI Study Attribution, Laboratory Tests,
Case Report Forms
Clinical Research Information
Management System of the NIAID
(CRIMSON)
NIAID NIAID Study-Subject Attribution, Laboratory
Tests, Medications, Patient Problems
Clinical Research Database (CRDB) NIAAA NIAAA Assessments (Surveys)
Labmatrix* NHGRI Commercial Biospecimens, Case Report Forms
* Labmatrix installation at NHGRI is a separate server from the NCI installation and requires additional data import steps.
A.3. Overview of CDISC PRM protocol template sections
Section Content (relevant ICH E6 guideline criterion)
Introduction  Protocol Title, number, sponsor, protocol version and document date
 Investigational product (ICH 6.1.1)
 Relevant non-clinical prior studies (ICH 6.2.2)
 Known and potential risks and beneﬁts to human subjects (ICH 6.2.3)
 Statement indicating adherence to GCP and regulatory requirements (ICH 6.2.5)
 References to prior background literature and data relevant to the trial (ICH 6.2.7)
Study Objectives  Primary, secondary and other objectives (ICH 6.3)
Study design  Design summary (ICH 6.4)
 Schematic diagram of trial stages and procedures (ICH 6.4.2)
 Primary and secondary endpoints measured during the trial (ICH 6.4.1)
 Strategies for controlling bias (eg, randomization) (ICH 6.4.3)
 Maintenance of trial treatment randomization codes and procedures for breaking codes.
(ICH 6.4.8)
 Blinding (ICH 6.4.3b)
Study schedule  Expected duration for participants and description of trial intervals (including follow-up)
(ICH 6.4.5)
Treatment  Trial treatment arms, dosage regiment, packaging and labeling (ICH 6.4.4)
 Description of ‘‘stopping rules’’ or ‘‘discontinuation criteria’’ (ICH 6.4.6)
 Concomitant medication (ICH 6.6.2)
 Procedures for monitoring subject compliance (ICH 6.6.3)
(continued on next page)
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Section Content (relevant ICH E6 guideline criterion)
Study population  Inclusion criteria (ICH 6.5.1)
 Exclusion criteria (ICH 6.5.2)
 Subject withdrawal and replacement (ICH 6.5.3)
Assessment of scientiﬁc objectives
(Efﬁcacy)
 Efﬁcacy parameters for each outcome measure (ICH 6.7.1)
 Methods and timing for assessing, recording, and analyzing appropriate outcome
measures
 (ICH 6.7.2)
Assessment of safety  Speciﬁcation of parameters related to safety (ICH 6.8.1)
 Deﬁnition of adverse events (ICH 1.2)
 Adverse event reporting (ICH 6.8.3)
 Halting rules
Statistical plan  Statistical methods (ICH 6.9.1)
 Subject population (ICH 6.9.2)
 Study hypotheses
 Sample size calculations and considerations
 Planned level of statistical signiﬁcance (ICH 6.9.3)
 Termination criteria (ICH 6.9.4)
 Data accountability procedures (ICH 6.9.5)
 Deviation reporting (ICH 6.9.6)
Ethics  IRB approval documentation
 Informed consent process (ICH 4.8)
 Financing and insurance
Data handling and record keeping  Data storage policies
Publication policy  Deﬁnition of any publication limitations (if any)
Supplements  References
 Pharmaceuticals
 Schedule of assessments
 Standardized questionnaire instruments
 Informed consent
 Recruitment ads
A.4. WHO trial registration data set
The table below offers a listing of all 20 items required by WHO (version 1.2.1).
Detailed description of individual WHO items is available at http://www.who.int/ictrp/network/trds/en.
The second column shows how the minimum registration data requirements are addressed by the ClinicalTrials.gov registry. Items
marked by star (⁄) can currently be represented using ODM. Future ODM revisions or extensions should address the 13 unmarked items.
WHO trial registration data set ClinicalTrials.gov
1. Primary Registry and Trial Identifying Number ClinicalTrials.gov Identiﬁer (NCT Number) – assigned by system
2. Date of Registration in Primary Registry First registration date (generated)
3. Secondary Identifying Numbers Organization’s Unique Protocol ID Secondary IDs
4. Source(s) of Monetary or Material Support⁄ Sponsor, Collaborators
5. Primary Sponsor⁄ Sponsor
6. Secondary Sponsor(s)⁄ Collaborators
7. Contact for Public Queries⁄ Facility Contact OR Central Contact
8. Contact for Scientiﬁc Queries⁄ Overall Study Ofﬁcials
9. Public Title Brief Title
10. Scientiﬁc Title⁄ Ofﬁcial Title
11. Countries of Recruitment⁄ Facility – Country
12. Health Condition(s) or Problem(s) Studied Conditions or Focus of Study
13. Intervention(s) Intervention Type, Intervention Name, Intervention Description, Arm Label,
Arm Type, Arm Description
14. Key Inclusion and Exclusion Criteria⁄ Eligibility Criteria
15. Study Type Study Type, Allocation, Masking, Intervention Model, Primary Purpose,
Study Phase
16. Date of First Enrollment Study Start Date
17. Target Sample Size Enrollment
18. Recruitment Status Overall Recruitment Status
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WHO trial registration data set ClinicalTrials.gov
19. Primary Outcome(s) Primary Outcome Measure – Title, Description, Time Frame
20. Key Secondary Outcomes Secondary Outcome Measure – Title, Description, Time Frame
Source of mapping to ClinicalTrials.gov is http://prsinfo.clinicaltrials. gov/trainTrainer/WHO-ICMJE-ClinTrialsgov-Cross-Ref.pdf.
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Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jbi.2015.06.023.
References
[1] K. Dwan, D.G. Altman, L. Cresswell, M. Blundell, C.L. Gamble, P.R. Williamson,
Comparison of protocols and registry entries to published reports for
randomised controlled trials, Cochrane Database Syst. Rev. 1 (2011)
MR000031.
[2] F. Koenig, J. Slattery, T. Groves, et al., Sharing clinical trial data on patient level:
opportunities and challenges, Biometrical J. Biometrische Zeitschrift. 18 (6)
(2014).
[3] International Conference on Harmonisation: E6 (R1) Good Clinical Practice,
1996. <http://www.ich.org/products/guidelines/efﬁcacy/efﬁcacy-single/
article/good-clinical-practice.html> (accessed 28.05.14).
[4] ITN. Immunologist Effort Aims to Improve Hyperlinking of Research Papers to
Raw Data, 2014; <http://blogs.nature.com/spoonful/2013/07/immunologist-
effort-aims-to-improve-hyperlinking-of-research-papers-to-raw-data.html>
(accessed 15.09.14).
[5] i2b2 Community: ODM to i2b2 importer (Jonathan Bickel), 2014;
<https://community.i2b2.org/wiki/display/ODM2i2b2/Home> (accessed
15.06.14).
[6] B. Breil, J. Kenneweg, F. Fritz, et al., Multilingual medical data models in ODM
format: a novel form-based approach to semantic interoperability between
routine healthcare and clinical research, Appl. Clin. Inform. 3 (3) (2012) 276–
289.
[7] M. Dugas, S. Dugas-Breit, Integrated data management for clinical studies:
automatic transformation of data models with semantic annotations for
principal investigators, data managers and statisticians, PLoS ONE 9 (2) (2014)
e90492.
[8] G. Karam, Update on the Collaboration Between CDISC and WHO-ICTRP:
Registration of all Clinical Trials as a Scientiﬁc and Ethical Responsibility CDISC
InterChange (Europe), 2014.
[9] CDISC, CDISC DataSet-XML standard, 2014; <http://www.cdisc.org/dataset-
xml> (accessed 18.09.14).
[10] C. Weng, C. Batres, T. Borda, et al., A real-time screening alert improves patient
recruitment efﬁciency, AMIA Annu. Symp. Proc. 2011 (2011) 1489–1498.
[11] R.L. Richesson, P. Nadkarni, Data standards for clinical research data collection
forms: current status and challenges, J. Am. Med. Inform. Assoc. 18 (3) (2011)
341–346.
[12] R.L. Richesson, J. Krischer, Data standards in clinical research: gaps, overlaps,
challenges and future directions, J. Am. Med. Inform. Assoc. 14 (6) (2007) 687–
696 (November–December).
[13] ClinicalTrials.gov. Protocol Registration System, 2013; <http://prsinfo.
clinicaltrials.gov/> (accessed 8.02.13).
[14] NLM, Common Data Element (CDE) Resource Portal, 2014. <http://www.nlm.
nih.gov/cde> (accessed 12.01.15).
[15] CDISC, CDISC Shared Health and Clinical Research Electronic Library (SHARE),
2015 >http://www.cdisc.org/cdisc-share> (accessed 22.01.15).
[16] J.J. Cimino, E.J. Ayres, L. Remennik, et al., The national institutes of health’s
biomedical translational research information system (BTRIS): design,
contents, functionality and experience to date, J. Biomed. Inform. 19 (11)
(2013).
[17] D. Dominguez, M. Jawara, N. Martino, N. Sinaii, C. Grady, Commonly performed
procedures in clinical research: a benchmark for payment, Contemp. Clin.
Trials 33 (5) (2012) 860–868.
[18] M. Solutions, Protocol Outline Web-based Form Wizard, 2013; <https://
cdiscprm-sandbox.imedidata.net> (accessed 15.06.14).[19] P. Stratton, N. Sinaii, J. Segars, et al., Return of chronic pelvic pain from
endometriosis after raloxifene treatment: a randomized controlled trial,
Obstet. Gynecol. 111 (1) (2008) 88–96.
[20] B.I. Karp, N. Sinaii, L.K. Nieman, S.D. Silberstein, P. Stratton, Migraine in women
with chronic pelvic pain with and without endometriosis, Fertil. Steril. 95 (3)
(2011) 895–899.
[21] A.L. Hsu, N. Sinaii, J. Segars, L.K. Nieman, P. Stratton, Relating pelvic pain
location to surgical ﬁndings of endometriosis, Obstet. Gynecol. 118 (2 Pt 1)
(2011) 223–230.
[22] C. Weng, S.W. Tu, I. Sim, R. Richesson, Formal representation of eligibility
criteria: a literature review, J. Biomed. Inform. 43 (3) (2010) 451–467.
[23] F. Kopcke, B. Trinczek, R.W. Majeed, et al., Evaluation of data completeness in
the electronic health record for the purpose of patient recruitment into clinical
trials: a retrospective analysis of element presence, BMC Med. Inform. Decis.
Mak. 13 (2013) 37.
[24] CDISC, Charter of Clinical Trials Registration and Results (CTR&R) Group, 2014.
[25] Protocol Representation Group Charter, 2014; <http://www.cdisc.org/
system/ﬁles/all/standard/charter/2014PRGCharter_v1.pdf> (accessed
16.06.14).
[26] A. Vadakin, B. Hinkson, The CDISC Protocol Representation Model and Toolkit,
2012.
[27] CDISC. Protocol Representation Model Toolset v 1: Subset of Protocol Concepts
Composing the Protocol Outline (Access Requires free user Registration).
<http://cdisc.org/system/ﬁles/all/standard/application/zip/prm_tool_set___
study_outline_concepts.xlsx> (accessed 8.07.13).
[28] CDISC, Protocol Outline Template, 2012 <http://cdisc.org/system/ﬁles/
members/article/application/zip/prm_tool___study_outline_word_template_
.dotx>.
[29] WHO, WHO Trial Registration Data Set (Version 1.2.1). <http://www.who.int/
ictrp/network/trds/en/> (accessed 7.06.14).
[30] E. Jaritz, Bachelor Thesis: XSLT for the Representation of ClinicalTrials.gov XML
in a Web Browser (Graz University of Applied Sciences), 2013.
[31] HL7, HL7 Version 3 Domain Analysis Model: Clinical Trials Registration and
Results (CTR&R), Release 1, 2011 <http://www.hl7.org/implement/standards/
product_brief.cfm?product_id=153> (accessed 20.05.14).
[32] O. Bodenreider, D. Nguyen, P. Chiang, et al., The NLM value set authority
center, Stud. Health Technol. Inform. 192 (2013) 1224.
[33] C. Tao, J. Pathak, H.R. Solbrig, W.Q. Wei, C.G. Chute, Terminology
representation guidelines for biomedical ontologies in the semantic web
notations, J. Biomed. Inform. 46 (1) (Feb 2013) 128–138.
[34] CDISC, Clinical Data Acquisition Standards Harmonization (CDASH), 2014
<http://www.cdisc.org/cdash> (accessed 20.01.15).
[35] M.M. Mello, J.K. Francer, M. Wilenzick, P. Teden, B.E. Bierer, M. Barnes,
Preparing for responsible sharing of clinical trial data, N. Engl. J. Med. 369 (17)
(2013) 1651–1658.
[36] YODA, YODA Project Policies and Procedures, 2014 <http://medicine.yale.
edu/core/projects/yodap/datasharing/Janssen/policies.aspx> (accessed
18.09.14).
[37] Federal Register: Request for Comments: Availability of Masked and De-
identiﬁed Non-Summary Safety and Efﬁcacy Data, 2013 <https://www.
federalregister.gov/articles/2013/06/04/2013-13083/availability-of-masked-
and-de-identiﬁed-non-summary-safety-and-efﬁcacy-data-request-for-
comments>.
[38] R. Kush, L. Alschuler, R. Ruggeri, et al., Implementing Single Source. the
STARBRITE proof-of-concept study, J. Am. Med. Inform. Assoc. 14 (5) (2007)
662–673 (September–October).
[39] A. El Fadly, B. Rance, N. Lucas, et al., Integrating clinical research with the
Healthcare Enterprise: from the RE-USE project to the EHR4CR platform, J.
Biomed. Inform. 44 (Suppl. 1) (Dec 2011) S94–102.
[40] CDISC, CDISC 2013 Annual Report: Data Sharing for the Beneﬁt of Patients,
2014 <http://www.cdisc.org/system/ﬁles/all/CDISC_AR_2013C-Pages-web(1).
pdf> (accessed 10.09.14).
